Why is Mangalam Drugs falling/rising?

As of 18-Sep, Mangalam Drugs and Organics Ltd is currently priced at 75.00, showing no change (0.00%). The stock has underperformed its sector by 1.05% today and is trading below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages. Over the past week, the stock has declined by 2.52%, and it has seen a significant drop of 44.81% over the last year, while its profits have plummeted by 399.4%. The company has reported operating losses and negative results for the last two consecutive quarters, contributing to its weak long-term fundamental strength. Additionally, the company's ability to service its debt is compromised, indicated by a poor EBIT to Interest ratio of 1.73, further impacting investor confidence.
In the broader market context, the stock's recent performance contrasts sharply with the benchmark, as the Sensex has gained 1.80% over the past week and 6.24% year-to-date. This consistent underperformance against the benchmark over the last three years highlights the challenges faced by Mangalam Drugs, which has generated negative returns in each of the last three annual periods. The decline in net sales by 21.48% and the low profitability per unit of shareholders' funds, as evidenced by a Return on Equity of 7.99%, further underscores the stock's struggles in a market that is otherwise showing positive trends.